Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyCapital Bluecross 9p21 genotyping Coverage Update …
    Ask Trek AI about this page
    RetiredCapital BluecrossPolicy MP 2.311

    Genotyping for 9p21 Single Nucleotide Polymorphisms

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 2.311 alerts

    Get alerted when Policy MP 2.311 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage stance for genotyping of 9p21 SNPs to predict cardiovascular disease or aneurysm risk for Capital Bluecross members and applies to programs and products administered by Capital Bluecross as noted.

    Policy Summary
    PayerCapital Bluecross
    PolicyGenotyping for 9p21 Single Nucleotide Polymorphisms
    Policy CodePolicy MP 2.311
    Change TypeRetirement review / delegation noted
    Effective DateJul 1, 2026
    Last ReviewMar 9, 2026
    Next Review DateMar 9, 2026
    Key ActionUse of genotyping for 9p21 SNPs is investigational for all clinical uses and would be denied; follow delegated utilization management (EviCore) where applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Investigationalcoverage stance for 9p21 genotyping
    CPT 81479procedure code called out as investigational for this test
    193,372meta-analysis size
    HR 1.19risk increase per allele

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    EviCore
    utilization management

    Coverage Criteria — 9p21 Genotyping

    Investigational / Not Medically Necessary

    Not covered/investigational:

    Investigational Uses: Genotyping for 9p21 SNPs is investigational for all clinical uses, including but not limited to identification of patients who may be at increased risk of cardiovascular disease or its manifestations (e.g., myocardial infarction, ischemic stroke, peripheral arterial disease, coronary artery calcification) or identification of patients who may be at increased risk of aneurysmal disease (abdominal aortic aneurysm, intracranial aneurysm, polypoidal choroidal vasculopathy).

    There is insufficient evidence that 9p21 genotyping improves health outcomes, risk reclassification beyond traditional risk factors, or changes management; clinical utility has not been established.

    This policy applies to genotyping for 9p21 single nucleotide polymorphisms for members of programs and products administered by Capital Blue Cross. Applicability may vary by program or product, and benefit variations or prior authorization requirements should be checked for the specific plan. For Federal Employee Program (FEP PPO) members, refer to the FEP Medical Policy Manual at the FEP website referenced in the policy.

    Providers should verify product-specific coverage rules and any delegated utilization management processes before ordering or billing for 9p21 genotyping, since the policy is not uniformly applied across all administrative programs.

    The policy references recommendations from the EGAPP Working Group on genomic profiling to assess cardiovascular risk. These EGAPP recommendations are cited as part of the evidence base considered in the policy when evaluating the clinical utility of genomic profiling for cardiovascular risk assessment.

    The policy concludes that there is insufficient evidence that genotyping for 9p21 SNPs leads to improved health outcomes or changes in patient management. Although 9p21 variants show consistent association with coronary heart disease, studies have not demonstrated that testing with 9p21 influences clinical decisions, leads to different management, or improves outcomes; therefore the procedure is considered investigational for all clinical uses.

    No studies were identified that directly evaluate whether using 9p21 genotyping results in changes to patient management or in improved clinical outcomes, and the evidence is judged insufficient to determine effects on health outcomes or to support routine clinical implementation.

    Evidence summaries note that while the clinical validity of 9p21 polymorphisms for coronary artery/heart disease (CAD/CHD) is well-established and consistent across multiple populations, the addition of 9p21 genotyping to traditional risk factors has not been shown to reliably improve risk reclassification. Some studies cited report that 9p21 variation may explain a proportion of disease incidence but does not improve risk prediction in certain cohorts.

    Specific literature cited in the policy includes systematic reviews and individual studies that found limited or no incremental predictive utility for 9p21 genotype beyond conventional risk factors, and no identified studies demonstrating that testing changes management or clinical outcomes. These limitations underpin the investigational determination.

    Coding — Procedure and Billing Codes

    Investigational CPT Codes for 9p21 genotypingCPTNot Covered
    81479Unlisted molecular pathology procedure

    Provider Actions and Billing Guidance

    Prior Authorization

    Check product/program benefit variations and prior authorization rules

    Verify product- and program-specific applicability before ordering or billing. This policy applies only to certain programs and products administered by Capital Blue Cross and is subject to benefit variations; check member benefit information and any FEP (Federal Employee Program) variations referenced in the policy prior to submission.

    • Policy applicability may vary by product/program; FEP follows FEP Medical Policy Manual as noted in policy variations.
    • Coverage is determined by member benefit terms; identification of a code in the coding section does not denote coverage.
    Note

    Follow EviCore delegation for utilization management

    Follow delegated utilization management processes as indicated. The Retirement Review dated 03/09/2026 documents EviCore delegation, which indicates prior authorization and utilization management for this service may be managed by EviCore per payer administrative processes.

    • Confirm whether EviCore now handles prior authorization or other utilization management functions for this test.

    Background — 9p21 Locus and Clinical Context

    Variants at the 9p21 locus (also referred to as 9p21.3) are a cluster of highly correlated single nucleotide polymorphisms located on chromosome 9 spanning roughly 58 kb and are associated with increased risk of coronary heart disease and myocardial infarction.

    Multiple independent populations and meta-analyses have established the clinical validity of the association between 9p21 variation and CAD/CHD, with evidence of increasing severity of outcomes with greater risk allele dosage; however, associations with ischemic stroke, aneurysms, and other vascular phenotypes are less well-studied and less certain.

    Definitions

    9p21 (9p21.3) locus — definition and clinical associations
    Locus locationChromosome 9p21 (often specified as 9p21.3)
    Genomic spanApproximately a 58-kilobase region at 9p21.3
    SNP correlationMultiple SNPs in the locus are highly correlated (r2 > 0.8) and in linkage disequilibrium
    Clinical associationsAssociated with coronary heart disease (CHD) and myocardial infarction (MI), including early-onset MI; also linked to ischemic stroke, abdominal aortic aneurysm, intracranial aneurysm, and other vascular diseases
    Independence from traditional risk factorsAssociation with CHD risk shown to be independent of traditional cardiovascular risk factors
    9p21 variants — definition and evidence linking SNPs to CAD/MI
    Policy Summary
    PayerCapital Bluecross
    PolicyGenotyping for 9p21 Single Nucleotide Polymorphisms
    Policy CodePolicy MP 2.311
    Change TypeRetirement review / delegation noted
    Effective DateJul 1, 2026
    Last ReviewMar 9, 2026
    Next Review DateMar 9, 2026
    Key ActionUse of genotyping for 9p21 SNPs is investigational for all clinical uses and would be denied; follow delegated utilization management (EviCore) where applicable.
    SourceLink
    On This Page
    Coverage Criteria — 9p21 GenotypingCoding — Procedure and Billing CodesProvider Actions and Billing GuidanceBackground — 9p21 Locus and Clinical ContextDefinitions
  1. Follow EviCore submission and documentation requirements if delegation is in effect for the member's product.
  2. Documentation Required

    Document clinical rationale and follow delegated submission requirements

    Ensure any order or claim includes provider rationale and supporting documentation consistent with member benefits and delegated management requirements.

    • Document clinical indication and reasoning for testing in the medical record if the test is ordered.
    • If delegated (EviCore), follow their documentation checklist and prior authorization instructions.
    Step Therapy

    Note: consensus reviews — no step therapy specified

    Be aware that multiple consensus reviews resulted in no changes to the policy statement or coding; no step therapy requirements are specified in the policy history.

    • Consensus reviews dated 03/09/2020, 02/11/2021, 01/21/2022, 12/08/2023, 08/13/2025 noted no change to the policy statement or coding.
    • No step therapy criteria are specified in the policy history entries.
    Billing Rule

    Billing: use CPT 81479 (unlisted molecular pathology) when appropriate and document rationale

    When billing, use the appropriate code(s) and document the rationale for the code selected. There is no specific CPT code for this test; if specific analytes are not listed among analyte-specific CPTs, report the unlisted molecular pathology code 81479 and document why that code was used.

    • If the analyte is listed in CPT ranges 81200–81355 or 81400–81408, report the specific analyte CPT plus 81479 for analytes not listed.
    • If no analytes are listed with a specific CPT, report unlisted code 81479 for the whole test.
    • Document in the record the testing performed and the rationale for using an unlisted code (81479).
    Documentation Required

    Maintain documentation and verify coding per policy history and delegation

    Verify documentation and coding per policy history and follow delegated management guidance. Policy history entries document repeated consensus reviews and coding verification; providers should follow any delegated management (EviCore) and maintain documentation that supports the billed code and clinical indication.

    • Coding for this test (procedure code 81479) was identified and verified in policy history entries.
    • Maintain records of the clinical indication, test performed, and code-selection rationale to support claims or prior authorization requests.
    Denial Risk

    Investigational service — anticipate denial for 9p21 genotyping

    Do not expect coverage for genotyping of 9p21 SNPs; such testing is considered investigational and would be denied.

    • The policy states: 'The use of genotyping for 9p21 single nucleotide polymorphisms (SNPs) is considered investigational for all clinical uses.'
    • If submitted, claims for this service are subject to denial on investigational grounds.
    Note

    Delegation noted in retirement review — confirm coverage management with EviCore

    Note the administrative change recorded in the retirement review: EviCore delegation was documented on 03/09/2026; providers should confirm whether utilization management or prior authorization responsibilities have been transferred to EviCore for applicable products.

    • 03/09/2026 Retirement Review entry: 'EviCore Delegation.'
    • Confirm delegated processes before ordering or submitting claims.
    Variant typeSingle nucleotide polymorphisms (SNPs) located within the 9p21/9p21.3 locus
    Key findingsInitial GWAS in 2007 and subsequent replication studies identified common 9p21 SNPs associated with increased risk of CHD and MI
    Evidence baseMultiple large-scale association studies and meta-analyses (e.g., CARDIoGRAM, replication/meta-analyses cited) confirm association across populations
    Related phenotypes9p21 variants have been associated with coronary artery disease burden, angiographic severity/progression, ischemic stroke, and aneurysmal disease in multiple studies
    Representative referencesSelected citations include Schunkert et al. (large-scale association/meta-analyses) and multiple replication/meta-analysis studies listed in the policy references